They demonstrate that the SDF-1 gene-activated scaffold may overcome the limitations of diabetic AD-MSCs, creating opportunities for stem cell therapies in combination with new biomaterials to treat DFUs [133]. This evidence concerns the gene CXCL12 and Alzheimer disease.